Filling the gaps in the patient journey within an increasingly complex data environment.

In the third part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Joe Lipari, director of product management, Systech, predicts the probability that these DSCSA compliance deadlines put forth by the FDA will be met.

The latest news for pharma industry insiders.

A guide to overcoming the top obstacles facing patient services programs today.

The importance of embracing universal values and business models that prioritize humanity.

The companies will be financially committing $1 and $3 billion into their respective manufacturing facilities.

In the third part of this roundtable discussion, experts discuss the value of Michigan State University’s Axia Institute—including its RFID testing efforts—and dive into the Institute’s end-to-end RFID pilot that it has been conducting.

Addressing the bottlenecks in cell and gene therapy manufacturing through a well-designed artificial intelligence approach is essential to avoiding data siloes.

The latest news for pharma industry insiders.

Is the potential of a more formal policy integration for health issues and disease prevention a scary suggestion or a good Idea?

While the program could be a good option for many, it's not a panacea.

A crash course on the bubble itself, including therapeutic areas most affected.

In the second part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Joe Lipari, director of product management, Systech, comments on what the repercussions are for failing to comply with the DSCSA.

The latest news for pharma industry insiders.

In the first part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Joe Lipari, director of product management, Systech, describes the latest state of DSCSA implementation guidelines.

A qualitative analysis consisting of patients, care partners, and oncology clinicians measures the sources of time burdens, along with how these impact various individuals.

The latest news for pharma industry insiders.

Dr. Reddy’s immuno-oncology drug for the treatment of adults with recurrent or metastatic nasopharyngeal carcinoma will be marketed under the brand name Zytorvi.

The agreement provides PTC with $1 billion in cash once deal closes, and is centered around PTC518's development, manufacturing and commercialization.

The latest news for pharma industry insiders.

A total of 140 companies are being placed on the Entity List, in an effort to limit China’s effectiveness in the sector.

In the final part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Chase Feiger, MD, co-founder, Ostro, outlines the trends he expects to see over the next 10-15 years when it comes to the intersection of AI and life sciences.

The latest news for pharma industry insiders.

The transaction reaffirms the CDMO’s interest in growth on a global scale.

The latest news for pharma industry insiders.